BSI-737 / Biosion - LARVOL DELTA

BSI-737, a best-in-class B7H3xPD-L1 bi-specific ADC with dual function to eliminate tumor via selective killing and exacerbated anti-tumor immune response (AACR 2026) - "BSI-737 is a B7-H3 × PD-L1 bispecific ADC with best-in-class potential, leveraging dual targeting to enable selective tumor cell killing while amplifying anti-tumor immune responses. The current pre-clinical data highlight the potential of BSI-737 across expression levels of B7H3 and further pharmacokinetics, toxicity, and IND-enabling studies are underway."

ADC • Bispecific • IO biomarker • Oncology • CD276